{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178463","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.518321+00:00","generated_at":"2026-05-17T15:02:37.332299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation","bullets":["Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.","R&D expense $3.0M, down from $4.8M; SG&A $5.0M, down from $5.8M.","Cash $15.0M at June 30, 2025 vs $24.9M at Sep 30, 2024; burn funds clinical programs.","Phase 2b QUALITY: enobosarm 3mg + semaglutide preserved 100% lean mass (p<0.001) and increased fat loss 12% vs semaglutide alone.","Maintenance Extension: enobosarm 3mg monotherapy reduced weight regain by 46% after semaglutide discontinuation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178463","json":"https://secwatch.observer/filing/0001193125-25-178463.json","markdown":"https://secwatch.observer/filing/0001193125-25-178463.md","text":"https://secwatch.observer/filing/0001193125-25-178463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/0001193125-25-178463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/d59822d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:02:37.332299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}